QIAGEN- Development Programs in HPV Testing A Special Focus

First Clinical-Endpoint Trial: China, Jun 2007
• Wu Xiang County (n = 2380)
FastHPV performance in predicting cervical disease
• FastHPV testing performed same day on-site
• Testing performed by locally trained personnel
• Reference hc2 testing performed two weeks later in
advanced clinical lab in Beijing
•All women testing positive followed up with appropriate
clinical management…the same day
Test
hc2
FastHPV
VIA
Clinical Sensitivity
95%
86%
55%
Clinical Specificity
84%
86%
94%
FastHPV could reduce incidence of cervical cancer by as much as 56%
QIAGEN Analyst and Investor Day, February 14, 2008
Sample & Assay Technologies
The Status of FASThpv
• Clinical studies demonstrate:
FASThpv test produces rapid, accurate results
FASThpv is simple to run and requires minimal infrastructure
• The test will be cost-effective to governments and NGO’s for
public-health programs in qualifying countries.
• Moving quickly to leverage QIAGEN’s China-based industry
leading molecular diagnostic organization to successfully
manufacture, clinically validate and launch the FastHPV test in
China.
• The product is scheduled to be registered for approval in China
in H1 2009.
• Planning to follow our launch in China with similar efforts in India
QIAGEN Analyst and Investor Day, February 14, 2008
-26-
-27-
Sample & Assay Technologies
13